Organisation paid for research Program year 2023 Source: CMS Open Payments

William D Koltun MD

Neither a doctor nor a teaching hospital

Research payments

$5,837

24 payments

Through program year 2023, William D Koltun MD is reported as receiving $5,837 in research payments, across 24 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2023	Research	$347	1
2022	Research	$597	2
2021	Research	$1,380	12
2020	Research	$1,893	5
2019	Research	$1,622	4

Breakdown

Who paid Research payments · program years 2019–2023

Eli Lilly and Company $5,837 24 payments

Studies the money was for Research payments · program years 2019–2023

A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age With Episodic Migraine - the Rebuild Study $2,356 5 payments
Pediatric Options for Migraine Relief A Randomized, Double Blind, Placebo Controlled Study of Lasmiditan for Acute Treatment of Migraine Pioneer Peds1 $902 3 payments
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis $638 1 payment
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis $552 2 payments
Pediatric Options for Migraine Relief A Randomized Double Blind Placebo Controlled Study of Lasmiditan for Acute Treatment of Migraine Pioneer Peds1 $347 1 payment
A Randomized, Double Blind, Placebo Controlled Study of Galcanezumab in Adolescent Patients 12 to 17 Years of Age With Chronic Migraine the Rebuild 2 Study $344 3 payments
A Phase 3, 12 Month, Open Label Study of Lasmiditan in Pediatric Patients With Migraine Pioneer Peds2 $301 2 payments
A Randomized, Double-Blind Study With An Open-Label Extension Comparing the Effect of Once-Weekly Dulaglutide With Placebo in Pediatric Patients With Type 2 Diabetes Mellitus (Award-Peds: Assessment of Weekly Administration of Ly2189265 in Diabetes-Pediatric Study) $85 1 payment
A Randomized, Phase 3, Open Label Trial Comparing the Effect of the Addition of Tirzepatide Once Weekly Versus Insulin Lispro (U100) Three Times Daily in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With Or Without Metformin (Surpass 6) $77 1 payment
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $75 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.